Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eurofarma Heparin vs APP Heparin for VTE Prophylaxis in Hip Surgery
NCT01352039Phase 3Terminated
- Sponsor
- Eurofarma
- Start
- Oct 2011
- Primary completion
- Oct 2011
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of heparin in venous thromboembolism (VTE) (2 arms), sponsored by Eurofarma. Primary endpoint: Frequency of deep venous thrombosis at 6 months. Started Oct 2011; status: terminated.
02
Drugs
heparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT01352039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01352039.